- 18-FDG PET/CT Imaging and Clinical Decisions in Infective Endocarditis
- Autoantibodies and Clinical Symptoms in Infective Endocarditis Patients
- Beta-lactam Pharmacokinetics in Patients With Infective Endocarditis
- Betalactam Pharmacokinetics in Endocarditis Patients
- Cardiac Computarized Tomography in Infective Endocarditis
- Cardiac Surgery Peer Recovery Support Program
- Characteristics of Infective Endocarditis in East China
- Characterization of RadiOlabeled Tracer Uptake Pattern in Noninfected Transcatheter Aortic Valves.
- Clinical Metagenomics of Infective Endocarditis
- Contribution of PET/CT With Gallium 68 Citrate (68Ga-PET/CT) for the Diagnosis of Prosthetic Valve Infective Endocarditis
- CopenHeart IE – Integrated Rehabilitation of Patients Treated for Infective Endocarditis
- Detection of the Most Common Microorganism of Infective Endocarditis in Assiut University Hospital
- Does Whole Blood Adsorber During CPB Reduce Vasoactive Drugs Postoperatively in Endocarditis Patients Undergoing Valve Surgery?
- Early Clinical, Laboratory and Microbiological Predictors of Treatment Outcomes in Infective Endocaridtis
- Early Feasibility Study of Somatostatin Receptors PET Imaging for the Diagnosis of Infective Endocarditis
- Effect of Dexmedetomidine on Postoperative Renal Function in Infective Endocarditis Patients Undergoing Open Heart Surgery
- Endocarditis Registry of the University Hospital of Cologne (ER-UHC)
- Etiology of Endocarditis in Negative Blood Cultures
- Evaluation of a Metabolic Preparation by a Low-carbohydrate Diet as Atkins-diet to Help in Detecting Infective Endocarditis by 18F-FDG PET
- Evaluation of an Antibiotic Regimen Pharmacokinetic Applicable to Enterococcus Faecalis Infective Endocarditis
- Evaluation of Systemic Microvascular Endothelial Dysfunction in Patients Presenting With Infective Endocarditis
- Evolution of the Profile of Infectious Endocarditis in France in 2008 (EI2008)
- Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis
- French National Observatory on Infective Endocarditis
- Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients With Infective Endocarditis
- Hygiene and Bucco-dental Status of Patients With Oral Streptococcal Endocarditis
- Impact of Clinical Care Pathway on Prognosis and Therapeutic Medical Care of Infective Endocarditis
- Impact of Endothelial Cell Activation and Modifications of Haemostasis Induced by Infective Endocarditis on the Risk of Embolism
- Impact of FDG-PET/CT on Management of Patients With Native Valve Infective Endocarditis
- Impact of the Blood Culture Technique on the Diagnosis of Infective Endocarditis
- Incidence of Infective Endocarditis in End Stage Renal Disease Patients on Hemodialysis by Transesophageal Echocardiography in Assuit University Hospital
- Infective Endocarditis in Developing Countries, a Prospective, Observational, Multicentre Study
- Infective Endocarditis in the Elderly
- Inflammatory Mediator Profiles During Heart Valve Replacement Surgery
- NExt-Generation Sequencing and Cell Culture-based Characterization of S. Aureus in Infective Endocarditis
- Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus
- Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus
- Partial Oral Antimicrobials to Treat Infective Endocarditis in People Who Inject Drugs
- Personalized Medicine in Patients With Infective Endocarditis
- PET CT in Suspected CIED Infection, a Pilot Study – PET Guidance I
- PET/MR Imaging In Patients With Infective Endocarditis
- Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia
- Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
- Predisposition to Infectious Endocarditis
- PRetest prObability of Infectious ENDOCARDITIS for Appropriate Criteria Regarding Transesophageal ECHOcardiography in Tertiary Care Facilities (PRO ENDOCARDITIS ECHO-Study)
- Prospective Cohort Study of Patients With Infective Endocarditis at Pitié-Salpêtrière Hospital
- Rationale, Design and Methods for the Early Surgery in Infective Endocarditis Study (ENDOVAL)
- Reducing Risk for Infective Endocarditis
- Research Interest Antiphospholipid in Predicting Embolic Risk During Infective Endocarditis
- Retrospective Analysis of Nephrotoxicity During Daptomycin Versus Vancomycin Treatments in High Risk Patients
- Study of Leukocyte Immunophenotype and the Lipid Transport System as Predictive Biomarkers of Severe Bacterial Infections
- SURgical Registry of ENDocarditis EuRope
- Transcatheter Pulmonary Valve Implantation With SAPIEN 3 Valve
- Vancomycin, Gentamycin in Infective Endocarditis
Clinical Trials
- “Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer”
- A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
- A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
- Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer
- Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
- Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer
- Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
- Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
- Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
- Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer
- CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
- Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
- Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
- Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer
- Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer
- Denosumab as an add-on Neoadjuvant Treatment (GeparX)
- Dose-escalation Study of Oral CX-4945
- Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer
- Establishing an Inflammatory Breast Cancer Registry
- Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer
- Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
- Laser Optoacoustic and Ultrasonic Imaging System Assembly in Finding Changes in Tumors in Patients With Breast Cancer
- Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer
- Monitoring Response After The First Chemotherapy Cycle After Neoadjuvant Breast Cancer Therapy
- MUC1 Vaccine for Triple-negative Breast Cancer
- Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)
- Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer
- Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
- Olaparib and Radiotherapy in Inoperable Breast Cancer
- Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy
- Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
- Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
- Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia
- Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
- Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
- Refining Local-Regional Therapy for IBC
- Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
- Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
- Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer
- Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
- Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
- Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery
- Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
- Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy
- Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients
- [68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients
- A Multi-center Study to Evaluate the Efficacy and Safety of Pancreatic Duct Stents Placement Before the Enucleation of Insulinoma Located in the Head and Neck of the Pancreas Near the Main Pancreatic Duct
- CGM (Continuous Glucose Monitoring) Use in Diagnosis of Spontaneous and Reactive Hypoglycaemia
- Clinical Evaluation of 68Ga-NOTA-MAL-Cys39-exendin-4 Positron Emission Tomography in the Detection of Insulinoma
- Diagnosing and Treating Low Blood Sugar Levels
- EUS-guided Ethanol Ablation of an Insulinoma
- The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma
- Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients
- A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP®
- A Prospective Study of NuCel® in Cervical Spine Fusion
- A Study of SI-6603 in Patients With Lumbar Disc Herniation
- A Study of SI-6603 in Patients With Lumbar Disc Herniation
- Alternative and Integrative Therapy for Lumbar Disk Herniation
- Clinical and Radiological Evaluation of Patients With DDD Following TLIF With 3-D Printed Titanium Cage
- Clinical Trial Based on the Use of Mesenchymal Stem Cells From Autologous Bone Marrow in Patients With Lumbar Intervertebral Degenerative Disc Disease
- Efficacy Study of NuCel® in Patients Undergoing Fusion of the Lumbar Spine
- Observational Study on Effectiveness and Safety of Integrative Korean Medicine Treatment for Inpatients With Sciatica Due to Lumbar Intervertebral Disc Herniation
- PASS OCT® Post-market Clinical Follow-up
- Spine Surgery for Adhesions in Patients Evaluated for Efficacy and Safety of MedicurtainⓇ (Pivotal Study)
- The Synergy Disc for the Treatment of 2 Level Cervical Degenerative Disc Disease Compared With Cervical Fusion Surgery
- Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV)
- Validation of the STarT Back Screening Tool in the Military
- Efficacy and Safety of Fecal Microbiota Transplantation for Chronic Intestinal Pseudo-obstruction
- Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP)
- Improved Quality of Life in Children With Intestinal Failure
- Indiana University Gastrointestinal Motility Diagnosis Registry
- Pseudo-obstruction Assessment With MRI
- Rib Raising for Post-operative Ileus
- Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).
- Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations
- Clinical Trial for the Validation of AR Based Neuronavigation System
- Comparison of Imaging Quality Between Spectral Photon Counting Computed Tomography (SPCCT) and Dual Energy Computed Tomography (DECT)
- Evaluation of Nidus Occlusion After Gamma Knife Radiosurgery of Cerebral Arteriovenous Malformations Using Magnetic Resonance Imaging
- Functional Magnetic Resonance Imagine(fMRI)Navigation in Intracranial Arteriovenous Malformation Surgery
- Impact of CErebral Endovascular PROcedures on the Systemic Immune responSe Response
- Lovastatin for Treatment of Brain Arteriovenous Malformations
- MRI for the Early Evaluation of Acute Intracerebral Hemorrhage
- Multimodal Imaging Techniques in Assessing the Surgical Risk for Eloquent Arteriovenous Malformations
- Nationwide Treatment Survey of Intracranial Arteriovenous Malformation in China
- NIRS Monitoring During Intracranial Interventions
- Non-adhesive Liquid Embolic System in the Embolization of Cerebral Arteriovenous Malformations
- ONYX Evaluation in the Endovascular Treatment of Cerebral Arteriovenous Malformations (cAVM)
- Pediatric and Adult Cerebral Arteriovenous Malformation Neurofunctional Outcomes
- PHIL® Embolic System Pediatric IDE
- Protocol for Staged Stereotactic Radiosurgery for Large Arteriovenous Malformations
- Registry of Multimodality Treatment for Brain Arteriovenous Malformation in China
- Safety and Feasibility of the Infinity Catheter for Radial Access
- Surgical Management of Cerebral Arteriovenous Malformations Within Hybrid Operation Room
- Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent (CHOICE)
- Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent
- 90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
- A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC
- A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma
- A Single-arm Study of Gemcitabine, Cisplatin, and Nab-Paclitaxel as Neoadjuvant Therapy for Resectable Oncologically High-Risk IHCC in Korea
- A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma
- A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
- A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
- A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma
- A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
- A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
- A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma
- Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples
- Anti-PD1 Antibody Toripalimab Combined With Gemox as First-line Therapy in Late-stage Intrahepatic Cholangiocarcinoma
- Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
- Bortezomib in Intrahepatic Cholangiocellular Carcinoma
- Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma
- Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC
- Calcitriol in Advanced Intrahepatic Cholangiocarcinoma
- Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study
- Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery
- Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma
- Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma
- COmbination of Radiotherapy With Anti-PD-1 Antibody for unREseCtable inTrahepatic Cholangiocarcinoma
- Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma
- Contrast-Enhanced Ultrasound for the Prediction of Bile Duct Cancer Response to Radioembolization Treatment
- Conventional or Unconventional Lymph Node Dissection During Resection of Intrahepatic Cholangiocarcinoma
- Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
- DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma
- Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin
- Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
- Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
- Establishment of Scoring Model for Early and Differential Diagnosis of Intrahepatic Cholangiocarcinoma
- Expanded Access Use of Derazantinib for Advanced Intrahepatic Cholangiocarcinoma (iCCA) With FGFR Genomic Alterations
- Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
- Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers
- Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers
- Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer
- GOT Applied as Neoadjuvant Regimen for Patients of Resectable ICC With High-risk Factors of Recurrence
- GP Chemotherapy in Combination With Tislelizumab and Ociperlimab as First-line Treatment in Advanced BTC
- Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
- HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma
- HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma
- HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma
- HAIC Versus Systemic Chemotherapy for Unresectable ICC
- HAIC With FOLFOX Versus Systemic Chemotherapy With GP for Unresectable ICC
- Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
- Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma
- Hepatic Artery Infusion (HAI) Program at Duke University
- Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma
- Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
- Infusion System for Hepatic Cancer
- Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma
- Lenvatinib Plus PD-1 Antibody for Unresectable ICC
- Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
- Liver Transplantation for Early Intrahepatic Cholangiocarcinoma
- Liver Transplantation for Non-Resectable Intrahepatic Cholangiocarcinoma: a Prospective Exploratory Trial (TESLA Trial)
- Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC
- Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma
- mFOLFIRNOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
- Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis
- Next Generation Sequencing in Intrahepatic Cholangiocarcinoma
- PD-1 Antibody (SHR-1210) Plus Apatinib and Capecitabine in Patients With Intrahepatic Cholangiocarcinoma After Surgery
- Pemigatinib After SBRT or Other Minimally Invasive Technique in Advanced iCCA With FGFR2 Fusion/Rearrangements
- Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma
- Phase II Study Evaluating the Efficacy of M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma
- Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
- Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial
- Pressure Enabled Delivery of SD-101 With Checkpoint Blockade for Primary Liver Tumors
- Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases
- Prognosis of Resection and Radiotherapy in the Treatment of Intrahepatic Cholangiocarcinoma Patients
- Radiation Therapy vs. Observation Following Gemcitabine and Cisplatin for Inoperable Localized Liver Cancer
- Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer
- Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
- Regional or Extend LymphAdenectomy During Resection of Intrahepatic Cholangiocarcinoma
- Response of Hepatic Tumors to Radioembolization
- Role of Bile Duct Resection in Major Hepatectomy Due to Intrahepatic Cholangiocarcinoma
- Routine Lymphadenectomy for Intrahepatic Cholangiocarcinoma
- Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma
- Second Line Therapy for Advanced Intrahepatic Cholangiocarcinoma
- Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer
- Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma
- SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
- Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma
- Stereotactic Body Radiotherapy for Liver Tumors
- Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer
- Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery
- TACE Combined With “Target Immune” Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma
- TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma
- TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection
- Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver
- The Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Nab-paclitaxel Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
- Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer
- Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study
- Treat Primary and Metastatic Liver Tumors
- Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
- VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway
- VG161 in the Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
- Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
- A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)
- Bile Acid Effects in Fetal Arrhythmia Study
- Diet in Twin Pregnancy: the Wellness of Mother and Babies.
- Different Effects of Delayed Clamping on Neonatal Bilirubin Levels Between Pregnant Women With Intrahepatic Cholestasis of Pregnancy and Normal Pregnant Women
- Il-17 Levels in Intrahepatic Cholestasis of Pregnancy
- Liver Disease in Pregnancy
- Magnetic Resonance Imaging and Thermal Imaging of Adiposity in Neonates of Women With Metabolic Diseases
- P-wave Duration and Dispersion in Intrahepatic Cholestasis of Pregnancy
- Serum Autotaxin Levels in Cholestasis of Pregnancy
- Study on the Association of Intrahepatic Cholestasis of Pregnancy and Chronic Placental Inflammation, Reflect of the Allograft Rejection of Pregnancy
- The Metabolic Profile in Intrahepatic Cholestasis of Pregnancy and Diabetes Mellitus
- The Microbiome Composition in Women With Recurring Intrahepatic Cholestasis of Pregnancy (ICP)
- The Use of Fish Oil Supplementation in Treatment of Intrahepatic Cholestasis of Pregnancy
- Ursodeoxycholic Acid And Cholestasis Of Pregnancy
- A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2
- A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX
- A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX
- A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults
- A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers
- Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children
- Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine
- Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea
- Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51
- Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51
- Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440
- Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
- Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam
- Flavivirus Cross-priming Potential of IMOJEV
- Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination
- Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children
- Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling
- Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine
- Immunogenicity Study of the Japanese Encephalitis Vaccine IC51
- Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese Encephalitis
- Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age
- Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study
- Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51
- Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers
- Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj
- Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51
- Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine
- Post-licensure Safety Study of IMOJEV® in Thailand
- Postmarketing Surveillance Study for IMOJEV® in Republic of Korea
- Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51
- Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age
- Safety and Immunogenicity of JECEVAX in Young Children
- Safety and Tolerability of the Japanese Encephalitis Vaccine IC51
- Safety of Vero Cell – Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age
- Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.
- Safety Surveillance After Immunization With IXIARO
- Seroepidemiology of Japanese Encephalitis Virus Infection in Hualien, Taiwan
- Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province
- Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea
- Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers
- Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects
- Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines
- Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine
- This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population
- A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi’s Sarcoma
- A Phase II Trial of COL-3 in Patients With HIV Related Kaposi’s Sarcoma
- A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi’s Sarcoma in Zimbabwe
- A Study of Selumetinib in Patients With Kaposi’s Sarcoma
- A Study of sEphB4-HSA in Kaposi Sarcoma
- A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi’s Sarcoma
- Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
- An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
- Anti-Retrovirals for Kaposi’s Sarcoma
- Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi’s Sarcoma
- Assessment of Blood Vessel Density in Kaposi s Sarcoma Lesions
- BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi’s Sarcoma
- Bevacizumab to Treat Kaposi’s Sarcoma in HIV-Positive and HIV-Negative Patients
- Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
- Clinical, Laboratory and Epidemiologic Pilot Studies of Individuals at High Risk for Viral-Associated Cancers
- Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
- Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya
- Development of Serologic Assays for Human Herpes Virus-8
- Doxil/Caelyx BE Study
- Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma
- Effects of Maraviroc (MVC) on HIV-related Kaposi’s Sarcoma (KS)
- Effects of Potent Antiretroviral Therapy on Kaposi s Sarcoma
- Evaluating Quality of Life in Patients With AIDS-Associated Kaposi Sarcoma Treated With Bleomycin and Vincristine
- Evaluation of Advanced HIV Disease Differentiated Care Model in Malawi
- Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi’s Sarcoma and Lymphatic Drainage by SPECT/CT
- Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma
- Genetic Factors and Interrelationships for Sexual Orientation, Susceptibility to HIV and Kaposi’s Sarcoma, Alcoholism and Psychological Traits, and Histocompatibility Antigens
- Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi’s Sarcoma
- HHV8 and Solid Organ Transplantation
- History of the KSHV Inflammatory Cytokine Syndrome (KICS)
- HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT
- Interleukin-12 in Treating Patients With AIDS-Related Kaposi’s Sarcoma
- Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma
- Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
- Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
- Lenalidomide in Treating Patients With AIDS-Associated Kaposi’s Sarcoma
- Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
- Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
- NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
- Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
- NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
- Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
- Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi’s Sarcoma
- Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms
- Phase II Multicentric Study of Digoxin Per os in Classic or Endemic Kaposi’ s Sarcoma
- Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi’s Sarcoma
- Pomalidomide for Kaposi Sarcoma in People With or Without HIV
- Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma
- Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection
- Pomalidomide Treatment in Patients With Kaposi Sarcoma
- PTC299 in Treating Patients With HIV-Related Kaposi Sarcoma
- Risk Factors for Non-HIV-Related Kaposi s Sarcoma
- sEphB4-HSA in Treating Patients With Kaposi Sarcoma
- Smartphone Confocal Microscopy for Diagnosing Kaposi’s Sarcoma
- Strategies to Improve Kaposi Sarcoma (KS) Outcomes in Zimbabwe
- Studies of Human Herpesvirus 8 and Kaposi’s Sarcoma in Sicily
- Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma
- Suppression of Oral HHV8 Shedding With Valganciclovir
- Treatment With Indinavir and Chemotherapy for Advanced Classical Kaposi’s Sarcoma
- Trial of Ixazomib for Kaposi Sarcoma
- Valganciclovir Four Weeks Prior to cART Initiation Compared to Standard Therapy for Disseminated Kaposi Sarcoma
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity
- A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors
- Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma.
- Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma
- Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
- Sirolimus Plus Propranolol Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma